- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01265017
Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes
Single-center, Double-masked, Placebo-controlled Parallel-group Study of Pregnancy-related Hormones Estradiol and Medroxyprogesterone, in Conjunction With Hydrocortisone and Growth Hormone to Stimulate C-peptide Secretion in Women With T1DM
This is a randomized, double-masked, placebo-controlled, single-center study to evaluate stimulated C-peptide secretion after exogenous administration of mild immunosuppression and growth-promoting factors to women with preexisting T1DM who had a decline in insulin requirement or had detectable C-peptide during a previous pregnancy. Fifteen subjects will be enrolled and randomly assigned in a 2:1 ratio to either active treatment or placebo in a parallel group design.
Participation for individual subjects will consist of an initial Screening Visit, a 2-week baseline period, a Baseline Visit, visits at week 2 and 4 of the treatment period, a visit at the end of the treatment period (week 6), and a follow-up visit 2 weeks after study treatment discontinuation.
Subjects will receive either active treatment or matching placebo of estradiol 1 mg every 8 hours; medroxyprogesterone 2.5 mg every 24 hours; hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime each night; and growth hormone 2 mg once a day).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to determine whether women with preexisting T1DM who showed a decline in insulin requirement, defined as a decrease in insulin requirement of 25% or more, or a decrease deemed to be clinically significant by the investigator, with no other medically determined reason, or who had detectable C-peptide during a previous pregnancy will show a change in stimulated C peptide response when not pregnant and treated with exogenous pregnancy-related hormones and growth factors (Estradiol, medroxyprogesterone, hydrocortisone, GH) for 6 weeks.
The secondary objectives of this study are as follows:
- Determine whether the study treatment leads to a change in T1DM autoantibodies between Baseline and Week 6
- Determine the percentage of subjects experiencing a clinically significant decline in total daily insulin requirement at Week 6, defined as a 25% decrease from Baseline
- Descriptively evaluate the association between serum levels of growth hormone, cortisol, and prolactin and changes in C-peptide levels
- Evaluate the safety of administration of the study treatments compared with placebo, as measured by blood pressure, pulse, weight change, blood glucose, and adverse events (AEs)
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93105
- Sansum Diabetes Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female aged 18 years or older with T1DM and a documented history of at least one of the following:
- Decrease in insulin requirement with no other medically determined reason
- Detectable C-peptide
- Free of systemic corticosteroid use within 3 months before study entry.
- Stable weight (±10%)
- Stable diet and exercise
- Stable insulin requirement (<20% variability in insulin does in the 2 weeks prior to screening)Normal renal function as measured by an estimated glomerular filtration rate (simple MDRD)
- Negative pregnancy test and not planning to become pregnant during the study period. The subject must be willing to use an effective nonhormonal method of birth control during the study.
- Able to provide written informed consent.
Exclusion Criteria:
- Diagnosis of type 2 diabetes.
- Abnormal thyroid function (thyroid-stimulating hormone [TSH] and free thyroxine [FT4] test results) defined as TSH <0.4mIU/L or TSH>4.5mIU/L or Free T4 <0.6ng/dL or Free T4>1.6ng/dL.
- Abnormal renal function, as defined by serum creatinine greater than 1.2 mg/dL
- Any medical condition that, in the opinion of the investigator, yields the subject not suitable for study participation, including history of stroke, cancer, hypercoagulable problems, risk for deep vein thrombosis, and other unstable hormonal conditions, or Addison's disease or growth hormone deficiency.
- Currently treated with systemic steroids, hydrocortisone, growth hormone, or immunomodulatory medications
- Currently lactating.
- Pregnant within the last 9 months.
- Menopausal
- Taking hormonal therapy
- Known hypersensitivity to any of the medications used in this study or any component of the formulation.
- Known eating disorder
- History of phlebitis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Matching placebo
|
matching placebo
Other Names:
|
Experimental: Active Treatment
interventions include Estradiol, medroxyprogesterone, hydrocortisone, GH as follows
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
stimulated C-peptide response
Time Frame: 6 weeks
|
The primary efficacy endpoint is the Week 6 change from Baseline in stimulated C peptide response.
It will be modeled as a function of treatment group and baseline stimulated C peptide using an analysis of covariance model.
The assessment at the Screening Visit will serve as the baseline assessment in computing the C peptide change from baseline endpoint
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical, immunologic and hormonal responses
Time Frame: 6 weeks
|
The following secondary efficacy endpoint will be summarized descriptively and graphically by treatment group to which subjects were randomized: Week 6 changes from Baseline in the following: HbA1c, Total daily insulin requirement, IAA, GADA, IA-2A, ICA (pending the availability of sample processing, ZnT8A (pending the availability of sample processing), IGF-1, Prolactin, Growth hormone, Cortisol
|
6 weeks
|
Insulin requirement
Time Frame: 6 weeks
|
Proportion of subjects with a 25% or greater decrease from Baseline in total daily insulin requirement at Week 6
|
6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lois Jovanovic, MD, Sansum Diabetes Research Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Contraceptive Agents, Male
- Estradiol
- Hydrocortisone
- Hydrocortisone 17-butyrate 21-propionate
- Hydrocortisone acetate
- Hydrocortisone hemisuccinate
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
- Medroxyprogesterone Acetate
- Medroxyprogesterone
Other Study ID Numbers
- SDRI 2009-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Estradiol, medroxyprogesterone, hydrocortisone, GH
-
National Center for Research Resources (NCRR)University of Alabama at BirminghamCompletedSystemic Lupus ErythematosusUnited States
-
Brigham and Women's HospitalBayerCompletedCardiovascular DiseasesUnited States
-
Kayseri Education and Research HospitalCompletedApoptotic Signal Pathways in Endometrial HyperplasiaTurkey
-
Eli Lilly and CompanyCompleted
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Eunice Kennedy Shriver National Institute of Child...WithdrawnPremature Ovarian FailureUnited States
-
BayerCompletedHypertension | Postmenopause | Pre-HypertensionUnited States
-
Prince of Songkla UniversityCompleted
-
Mayo ClinicCompletedHealthyUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Postmenopause